title: Tranexamic acid administration after cardiac surgery: a prospective, randomized, double-blind, placebo-controlled study.
abstract: BACKGROUND
  Many different doses and administration schemes have been proposed for the use of the antifibrinolytic drug tranexamic acid during cardiac surgery. This study evaluated the effects of the treatment using tranexamic acid during the intraoperative period only and compared the results with the effects of the treatment continued into the postoperative period.
  
  
  METHODS
  Patients undergoing elective cardiac surgery with use of cardiopulmonary bypass (N = 510) were treated intraoperatively with tranexamic acid and then were randomized in a double-blind fashion to one of three postoperative treatment groups: group A: 169 patients, infusion of saline for 12 h; group B: 171 patients, infusion of tranexamic acid, 1 mg x kg(-1) x h(-1) for 12 h; group C: 170 patients, infusion of tranexamic acid, 2 mg x kg(-1) x h(-1) for 12 h. Bleeding was considered to be a primary outcome variable. Hematologic data, allogeneic transfusions, thrombotic complications, intubation time, and intensive care unit and hospital stay duration also were evaluated.
  
  
  RESULTS
  No differences were found among groups regarding postoperative bleeding and outcomes; however, the group treated with 1 mg x kg(-1) x h(-1) tranexamic acid required more units of packed red blood cells because of a significantly lower basal value of hematocrit, as shown by multivariate analysis.
  
  
  CONCLUSIONS
  Prolongation of treatment with tranexamic acid after cardiac surgery is not advantageous with respect to intraoperative administration alone in reducing bleeding and number of allogeneic transfusions. Although the prevalence of postoperative complications was similar among groups, there is an increased risk of procoagulant response because of antifibrinolytic treatment. Therefore, the use of tranexamic acid during the postoperative period should be limited to patients with excessive bleeding as a result of primary fibrinolysis.
authors.affiliation: Department of Anesthesiology, University of Milano, Italy. valter.casati@tin.it
authors.forename: V
authors.initials: V
authors.lastname: Casati
authors.forename: F
authors.initials: F
authors.lastname: Bellotti
authors.forename: C
authors.initials: C
authors.lastname: Gerli
authors.forename: A
authors.initials: A
authors.lastname: Franco
authors.forename: M
authors.initials: M
authors.lastname: Oppizzi
authors.forename: M
authors.initials: M
authors.lastname: Cossolini
authors.forename: G
authors.initials: G
authors.lastname: Calori
authors.forename: S
authors.initials: S
authors.lastname: Benussi
authors.forename: O
authors.initials: O
authors.lastname: Alfieri
authors.forename: G
authors.initials: G
authors.lastname: Torri
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000933:Antifibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002315:Cardiopulmonary Bypass; D015897:Comorbidity; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007432:Intraoperative Period; D008297:Male; D008875:Middle Aged; D019106:Postoperative Hemorrhage / Q000188:drug therapy / Q000517:prevention & control*; D011184:Postoperative Period; D012307:Risk Factors; D014148:Tranexamic Acid / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid